Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI-3 plus bevacizumab in metastatic colorectal adenocarcinoma
2006-005110-12Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Dec 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan and fluorouracil in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by CHU de Besançon. Primary endpoint: Best objective response. Started Dec 2006; status: completed.
02
Drugs
bevacizumabirinotecanfluorouracil
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-005110-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005110-12.